Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells
- 13 July 1995
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 93 (2), 147-155
- https://doi.org/10.1016/0304-3835(95)03795-x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I TrialJNCI Journal of the National Cancer Institute, 1993
- Apoptosis of Lung Cancer Cells Caused by Some Anti-cancer Agents (MMC, CPT-11, ADM) is Inhibited by BCL-2Biochemical and Biophysical Research Communications, 1993
- Effects of suramin on the proliferation of primary epithelial cell cultures derived from normal, benign hyperplastic and cancerous human prostatesThe Prostate, 1993
- Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6Nature, 1991
- Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell deathNature, 1990
- Synergistic Activity of Suramin With Tumor Necrosis Factor and Doxorubicin on Human Prostate Cancer Cell LinesJNCI Journal of the National Cancer Institute, 1990
- Suramin, an anti‐cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2AFEBS Letters, 1989
- Activation of a Ca2+−Mg2+‐dependent endonuclease as an early event in castration‐induced prostatic cell deathThe Prostate, 1988
- Role of iron in the proliferation of the established human tumor cell lines U‐937 and K‐562: Effects of suramin and a lipophilic iron chelator (PIH)Scandinavian Journal of Haematology, 1986
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976